MAOinhibiting
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that block the activity of the enzymes monoamine oxidase A and monoamine oxidase B, which normally degrade neurotransmitters such as serotonin, norepinephrine, and dopamine. By preventing the breakdown of these biogenic amines, MAOIs increase their availability in the brain and peripheral tissues, thereby exerting therapeutic effects.
The first MAOIs were introduced in the 1950s for the treatment of depression. Early compounds such as
MAOIs remain an important option for treatment‑resistant major depressive disorder, atypical depression, and certain anxiety disorders.
The primary limitation to widespread use of irreversible MAOIs is the risk of hypertensive crisis. This occurs
Because of drug–drug and food interactions, MAOIs require careful patient education and monitoring. Nonetheless, their unique